Cytokinetics (NASDAQ:CYTK) Downgraded by Cantor Fitzgerald to Neutral

Cantor Fitzgerald cut shares of Cytokinetics (NASDAQ:CYTK) from an overweight rating to a neutral rating in a research note issued to investors on Wednesday, November 22nd, MarketBeat.com reports. Cantor Fitzgerald currently has $10.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $21.00.

A number of other research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and set a $26.00 price objective on shares of Cytokinetics in a research report on Friday, October 27th. ValuEngine raised shares of Cytokinetics from a sell rating to a hold rating in a research report on Friday, September 1st. Seaport Global Securities reaffirmed a buy rating and set a $24.00 price objective on shares of Cytokinetics in a research report on Friday, October 6th. Morgan Stanley reaffirmed an overweight rating and set a $25.00 price objective (up from $24.00) on shares of Cytokinetics in a research report on Friday, October 6th. Finally, Zacks Investment Research cut shares of Cytokinetics from a buy rating to a hold rating in a research note on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $17.64.

Shares of Cytokinetics (NASDAQ CYTK) traded up $0.30 on Wednesday, reaching $8.10. 543,142 shares of the company were exchanged, compared to its average volume of 594,790. Cytokinetics has a 52-week low of $7.00 and a 52-week high of $17.20. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.04. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%. The firm had revenue of $6.18 million for the quarter, compared to the consensus estimate of $5.35 million. equities research analysts predict that Cytokinetics will post -2.4 EPS for the current year.

In other news, insider Caryn Gordon Mcdowell sold 4,260 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $12.94, for a total value of $55,124.40. Following the completion of the sale, the insider now directly owns 17,982 shares in the company, valued at $232,687.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.51, for a total transaction of $67,550.00. Following the completion of the sale, the chief executive officer now owns 70,180 shares of the company’s stock, valued at $948,131.80. The disclosure for this sale can be found here. Insiders sold 34,762 shares of company stock valued at $497,826 over the last quarter. Corporate insiders own 7.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Cytokinetics by 59.9% in the second quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock worth $37,721,000 after buying an additional 1,168,151 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Cytokinetics by 3.5% in the third quarter. Janus Henderson Group PLC now owns 2,778,605 shares of the biopharmaceutical company’s stock worth $40,290,000 after buying an additional 93,675 shares during the last quarter. State Street Corp lifted its stake in shares of Cytokinetics by 79.6% in the second quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock worth $20,259,000 after buying an additional 741,909 shares during the last quarter. Pinnacle Associates Ltd. acquired a new stake in shares of Cytokinetics in the third quarter worth $14,628,000. Finally, Citigroup Inc. raised its stake in Cytokinetics by 9.9% during the 2nd quarter. Citigroup Inc. now owns 800,471 shares of the biopharmaceutical company’s stock valued at $9,686,000 after purchasing an additional 71,811 shares during the last quarter. Institutional investors and hedge funds own 73.72% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2017/12/07/cytokinetics-incorporated-cytk-downgraded-by-cantor-fitzgerald.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply